BACKGROUND: MicroRNAs are regulators of gene expression, which act mainly by decreasing mRNA levels of their multiple targets. Deregulated microRNA expression has been shown for acute myeloid leukemia, a disease also characterized by altered gene expression associated with distinct genomic aberrations such as nucleophosmin (NPM1) mutations. To shed further light on the role of deregulated microRNA and gene expression in cytogenetically normal acute myeloid leukemia with NPM1 mutation we performed an integrative analysis of microRNA and mRNA expression data sets. DESIGN AND METHODS: Both microRNA and gene expression profiles were investigated in samples from a cohort of adult cytogenetically normal acute myeloid leukemia patients (n=43; median age 46 years, range 23-60 years) with known NPM1 mutation status (n=23 mutated, n=20 wild-type) and the data were integratively analyzed. Putative microRNA-mRNA interactions were validated by quantitative reverse transcriptase polymerase chain reaction, western blotting and luciferase reporter assays. For selected microRNAs, sensitivity of microRNA-overexpressing cells to cytarabine treatment was tested by FACS viability and cell proliferation assays. RESULTS: Our integrative approach of analyzing both microRNA- and gene expression profiles in parallel resulted in a refined list of putative target genes affected by NPM1 mutation-associated microRNA deregulation. Of 177 putative microRNA - target mRNA interactions we identified and validated 77 novel candidates with known or potential involvement in leukemogenesis, such as IRF2-miR-20a, KIT-miR-20a and MN1-miR-15a. Furthermore, our data showed that deregulated expression of tumor suppressor microRNAs, such as miR-29a and miR-30c, might contribute to sensitivity to cytarabine, which is observed in NPM1 mutated acute myeloid leukemia. CONCLUSIONS: Overall, our observations highlight that integrative data analysis approaches can improve insights into leukemia biology, and lead to the identification of novel microRNA - target gene interactions of potential relevance for acute myeloid leukemia treatment.
BACKGROUND: MicroRNAs are regulators of gene expression, which act mainly by decreasing mRNA levels of their multiple targets. Deregulated microRNA expression has been shown for acute myeloid leukemia, a disease also characterized by altered gene expression associated with distinct genomic aberrations such as nucleophosmin (NPM1) mutations. To shed further light on the role of deregulated microRNA and gene expression in cytogenetically normal acute myeloid leukemia with NPM1 mutation we performed an integrative analysis of microRNA and mRNA expression data sets. DESIGN AND METHODS: Both microRNA and gene expression profiles were investigated in samples from a cohort of adult cytogenetically normal acute myeloid leukemiapatients (n=43; median age 46 years, range 23-60 years) with known NPM1 mutation status (n=23 mutated, n=20 wild-type) and the data were integratively analyzed. Putative microRNA-mRNA interactions were validated by quantitative reverse transcriptase polymerase chain reaction, western blotting and luciferase reporter assays. For selected microRNAs, sensitivity of microRNA-overexpressing cells to cytarabine treatment was tested by FACS viability and cell proliferation assays. RESULTS: Our integrative approach of analyzing both microRNA- and gene expression profiles in parallel resulted in a refined list of putative target genes affected by NPM1 mutation-associated microRNA deregulation. Of 177 putative microRNA - target mRNA interactions we identified and validated 77 novel candidates with known or potential involvement in leukemogenesis, such as IRF2-miR-20a, KIT-miR-20a and MN1-miR-15a. Furthermore, our data showed that deregulated expression of tumor suppressor microRNAs, such as miR-29a and miR-30c, might contribute to sensitivity to cytarabine, which is observed in NPM1 mutated acute myeloid leukemia. CONCLUSIONS: Overall, our observations highlight that integrative data analysis approaches can improve insights into leukemia biology, and lead to the identification of novel microRNA - target gene interactions of potential relevance for acute myeloid leukemia treatment.
Authors: Mark Lutherborrow; Adam Bryant; Vivek Jayaswal; David Agapiou; Catalina Palma; Yee Hwa Yang; David D F Ma Journal: Am J Hematol Date: 2011-01 Impact factor: 10.047
Authors: Violaine Havelange; Nicole Stauffer; Catherine C E Heaphy; Stefano Volinia; Michael Andreeff; Guido Marcucci; Carlo M Croce; Ramiro Garzon Journal: Cancer Date: 2011-03-31 Impact factor: 6.860
Authors: Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner Journal: Blood Date: 2005-07-28 Impact factor: 22.113
Authors: Christian Langer; Guido Marcucci; Kelsi B Holland; Michael D Radmacher; Kati Maharry; Peter Paschka; Susan P Whitman; Krzysztof Mrózek; Claudia D Baldus; Ravi Vij; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Neha Patel; David Hoang; Nathan Miller; Sara Ansaloni; Qihong Huang; Jack T Rogers; Jeremy C Lee; Aleister J Saunders Journal: Mol Neurodegener Date: 2008-08-06 Impact factor: 14.195
Authors: Velizar Shivarov; Anna Dolnik; Katharina M Lang; Jan Krönke; Florian Kuchenbauer; Peter Paschka; Verena I Gaidzik; Hartmut Döhner; Richard F Schlenk; Konstanze Döhner; Lars Bullinger Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Francesca Lovat; Giovanni Nigita; Rosario Distefano; Tatsuya Nakamura; Pierluigi Gasparini; Luisa Tomasello; Paolo Fadda; Narmin Ibrahimova; Silvia Catricalà; Alexey Palamarchuk; Michael A Caligiuri; Anna Gallì; Luca Malcovati; Mark D Minden; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2020-05-18 Impact factor: 11.205
Authors: Frank G Rücker; Katharina M Lang; Markus Fütterer; Vladimir Komarica; Mathias Schmid; Hartmut Döhner; Richard F Schlenk; Konstanze Döhner; Steen Knudsen; Lars Bullinger Journal: Epigenetics Date: 2016-06-16 Impact factor: 4.528
Authors: Chi Keung Cheng; Tsz Ki Kwan; Chi Ying Cheung; Kitty Ng; Pei Liang; Suk Hang Cheng; Natalie P H Chan; Rosalina K L Ip; Raymond S M Wong; Vincent Lee; Chi Kong Li; Sze Fai Yip; Margaret H L Ng Journal: Haematologica Date: 2012-10-12 Impact factor: 9.941